<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD04490000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P00742</UniProt_ID>
  <Seq_Length>488</Seq_Length>
  <Molecule_Weight>54732</Molecule_Weight>
  <KEGG_ID>hsa:2159</KEGG_ID>
  <Orthology_ID>K01314</Orthology_ID>
  <Function_Summary>Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.</Function_Summary>
  <Catalytic_Mechanism>Selective cleavage of Arg-|-Thr and then Arg-|-Ile bonds in prothrombin to form thrombin.</Catalytic_Mechanism>
  <Pfam_ID>PF00008:EGF@@PF00594:Gla@@PF00089:Trypsin</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>7</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Factor X heavy chain</Alias>
      <Alias>Activated factor Xa heavy chain</Alias>
      <Alias>Factor X light chain</Alias>
      <Alias>Stuart factor</Alias>
      <Alias>Stuart-Prower factor</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with calcium ions (Ca2+).</Detail>
      <Keyword>Calcium ion binding</Keyword>
      <Ontology_ID>GO:0005509</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.</Detail>
      <Keyword>Peptidase activity</Keyword>
      <Ontology_ID>GO:0008233</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type peptidase activity</Keyword>
      <Ontology_ID>GO:0008236</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with phospholipids, a class of lipids containing phosphoric acid as a mono- or diester.</Detail>
      <Keyword>Phospholipid binding</Keyword>
      <Ontology_ID>GO:0005543</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type endopeptidase activity</Keyword>
      <Ontology_ID>GO:0004252</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.</Detail>
      <Keyword>Hydrolase activity</Keyword>
      <Ontology_ID>GO:0016787</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).</Detail>
      <Keyword>Protein binding</Keyword>
      <Ontology_ID>GO:0005515</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>289</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>327</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>404</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>47</Position>
      <Original>Glu</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>374</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>30</Position>
      <Original>Gln</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>390</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>72</Position>
      <Original>Glu</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>406</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>151</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>350</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>149</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>322</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>192</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>366</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>420</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>54</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>358</Position>
      <Original>Thr</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>383</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>304</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>51</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>54</Position>
      <Original>Glu</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>152</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>448</Position>
      <Original>Lys</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>142</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>338</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>91</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>363</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>7</Position>
      <Original>Leu</Original>
      <Variation>Ile</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.</Detail>
      <Keyword>Blood coagulation</Keyword>
      <Ontology_ID>GO:0007596</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A protein activation cascade that contributes to blood coagulation and consists of the self-limited process linking exposure and activation of tissue factor to the activation of clotting factor X.</Detail>
      <Keyword>Blood coagulation, extrinsic pathway</Keyword>
      <Ontology_ID>GO:0007598</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.</Detail>
      <Keyword>Proteolysis</Keyword>
      <Ontology_ID>GO:0006508</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The gamma-carboxylation of peptidyl-glutamic acid; catalyzed by the vitamin K dependent gamma-glutamyl carboxylase.</Detail>
      <Keyword>Peptidyl-glutamic acid carboxylation</Keyword>
      <Ontology_ID>GO:0017187</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The covalent alteration of one or more amino acids occurring in a protein after the protein has been completely translated and released from the ribosome.</Detail>
      <Keyword>Post-translational protein modification</Keyword>
      <Ontology_ID>GO:0043687</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the protein kinase B signaling cascade, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.</Detail>
      <Keyword>Positive regulation of protein kinase B signaling cascade</Keyword>
      <Ontology_ID>GO:0051897</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cell migration.</Detail>
      <Keyword>Positive regulation of cell migration</Keyword>
      <Ontology_ID>GO:0030335</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A protein activation cascade that contributes to blood coagulation and consists of the interactions among high molecular weight kininogen, prekallikrein, and factor XII that lead to the activation of clotting factor X.</Detail>
      <Keyword>Blood coagulation, intrinsic pathway</Keyword>
      <Ontology_ID>GO:0007597</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The stopping of bleeding (loss of body fluid) or the arrest of the circulation to an organ or part.</Detail>
      <Keyword>Hemostasis</Keyword>
      <Ontology_ID>GO:0007599</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>59</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>69</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>46</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>56</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>66</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>65</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>103</Position>
      <PTM_Type>(3R)-3-hydroxyaspartate</PTM_Type>
    </PTM>
    <PTM>
      <Position>60</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>47</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>79</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>54</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>72</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEETCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKNCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERRKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQECKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSGGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPEVITSSPLK</Protein_Seq>
    <DNA_Seq>GACTTTGCTCCAGCAGCCTGTCCCAGTGAGGACAGGGACACAGTACTCGGCCACACCATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTCGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGGGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAGACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTCTGGAATAAATACAAAGATGGCGACCAGTGTGAGACCAGTCCTTGCCAGAACCAGGGCAAATGTAAAGACGGCCTCGGGGAATACACCTGCACCTGTTTAGAAGGATTCGAAGGCAAAAACTGTGAATTATTCACACGGAAGCTCTGCAGCCTGGACAACGGGGACTGTGACCAGTTCTGCCACGAGGAACAGAACTCTGTGGTGTGCTCCTGCGCCCGCGGGTACACCCTGGCTGACAACGGCAAGGCCTGCATTCCCACAGGGCCCTACCCCTGTGGGAAACAGACCCTGGAACGCAGGAAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCGGGGAGGCCCCTGACAGCATCACATGGAAGCCATATGATGCAGCCGACCTGGACCCCACCGAGAACCCCTTCGACCTGCTTGACTTCAACCAGACGCAGCCTGAGAGGGGCGACAACAACCTCACCAGGATCGTGGGAGGCCAGGAATGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGCTCATCAATGAGGAAAACGAGGGTTTCTGTGGTGGAACCATTCTGAGCGAGTTCTACATCCTAACGGCAGCCCACTGTCTCTACCAAGCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGAACACGGAGCAGGAGGAGGGCGGTGAGGCGGTGCACGAGGTGGAGGTGGTCATCAAGCACAACCGGTTCACAAAGGAGACCTATGACTTCGACATCGCCGTGCTCCGGCTCAAGACCCCCATCACCTTCCGCATGAACGTGGCGCCTGCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCACGCTGATGACGCAGAAGACGGGGATTGTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCCGGCAGTCCACCAGGCTCAAGATGCTGGAGGTGCCCTACGTGGACCGCAACAGCTGCAAGCTGTCCAGCAGCTTCATCATCACCCAGAACATGTTCTGTGCCGGCTACGACACCAAGCAGGAGGATGCCTGCCAGGGGGACAGCGGGGGCCCGCACGTCACCCGCTTCAAGGACACCTACTTCGTGACAGGCATCGTCAGCTGGGGAGAGGGCTGTGCCCGTAAGGGGAAGTACGGGATCTACACCAAGGTCACCGCCTTCCTCAAGTGGATCGACAGGTCCATGAAAACCAGGGGCTTGCCCAAGGCCAAGAGCCATGCCCCGGAGGTCATAACGTCCTCTCCATTAAAGTGAGATCCCACTCAAAAAAAAAAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Plasma</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Liver</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Intrinsic to external side of plasma membrane</CellLocal>
      <Ontology_ID>GO:0031233</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endoplasmic reticulum lumen</CellLocal>
      <Ontology_ID>GO:0005788</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Golgi lumen</CellLocal>
      <Ontology_ID>GO:0005796</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>F10</Gene_Name>
    <Gene_ID>2159</Gene_ID>
    <Genbank_ACCN>NM_000504</Genbank_ACCN>
    <Protein_ACCN>NP_000495</Protein_ACCN>
    <HGNC_ID>3528</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/2159</Gene_URL>
    <UCSC_ID>uc001vsx.3</UCSC_ID>
    <EMBL_ID>ENSG00000126218</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Afibrinogenemia</Disease_Name>
      <Disease_Detail>Afibrinogenemia</Disease_Detail>
      <Disease_DB>AFB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/afibrinogenemia?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mild Hemophilia a</Disease_Name>
      <Disease_Detail>Hemophilia</Disease_Detail>
      <Disease_DB>MLD013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mild_hemophilia_a?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acquired Hemophilia</Disease_Name>
      <Disease_Detail>Acquired Hemophilia</Disease_Detail>
      <Disease_DB>ACQ014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acquired_hemophilia?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemophilia B</Disease_Name>
      <Disease_Detail>Hemophilia</Disease_Detail>
      <Disease_DB>HMP004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemophilia_b?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Scott Syndrome</Disease_Name>
      <Disease_Detail>Scott Syndrome</Disease_Detail>
      <Disease_DB>SCT005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/scott_syndrome?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Vii Deficiency</Disease_Name>
      <Disease_Detail>Factor Vii Deficiency</Disease_Detail>
      <Disease_DB>FCT007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_vii_deficiency?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Venous Thromboembolism</Disease_Name>
      <Disease_Detail>Venous Thromboembolism</Disease_Detail>
      <Disease_DB>VNS010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/venous_thromboembolism?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Quebec Platelet Disorder</Disease_Name>
      <Disease_Detail>Quebec Platelet Disorder</Disease_Detail>
      <Disease_DB>QBC001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/quebec_platelet_disorder?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myocardial Infarction</Disease_Name>
      <Disease_Detail>Myocardial Infarction</Disease_Detail>
      <Disease_DB>MYC007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myocardial_infarction?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Antithrombin Iii Deficiency</Disease_Name>
      <Disease_Detail>Antithrombin Iii Deficiency</Disease_Detail>
      <Disease_DB>ANT009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/antithrombin_iii_deficiency?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Heparin-Induced Thrombocytopenia</Disease_Name>
      <Disease_Detail>Heparin-Induced Thrombocytopenia</Disease_Detail>
      <Disease_DB>HPR003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/heparin_induced_thrombocytopenia?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dysfibrinogenemia</Disease_Name>
      <Disease_Detail>Dysfibrinogenemia</Disease_Detail>
      <Disease_DB>DYS026</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dysfibrinogenemia?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor X Deficiency</Disease_Name>
      <Disease_Detail>Factor X Deficiency</Disease_Detail>
      <Disease_DB>FCT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_x_deficiency?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemophilia</Disease_Name>
      <Disease_Detail>Hemophilia</Disease_Detail>
      <Disease_DB>HMP007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemophilia?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Al Amyloidosis</Disease_Name>
      <Disease_Detail>Al Amyloidosis</Disease_Detail>
      <Disease_DB>ALM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/al_amyloidosis?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Artery Disease</Disease_Name>
      <Disease_Detail>Artery Disease</Disease_Detail>
      <Disease_DB>ART111</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/artery_disease?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemarthrosis</Disease_Name>
      <Disease_Detail>Hemarthrosis</Disease_Detail>
      <Disease_DB>HMR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemarthrosis?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Carotid Artery Thrombosis</Disease_Name>
      <Disease_Detail>Carotid Artery Thrombosis</Disease_Detail>
      <Disease_DB>CRT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/carotid_artery_thrombosis?search=F10#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thromboembolism</Disease_Name>
      <Disease_Detail>Thromboembolism</Disease_Detail>
      <Disease_DB>THR079</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thromboembolism?search=F10#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Human coagulation factor Xa in complex with M54476</PDB_Title>
      <PDB_ID>1IQL</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IQL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor Xa Specific Inhibitor that Induces the Novel Binding Model in Complex with Human Fxa</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Factor XA in complex with the inhibitor 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423)</PDB_Title>
      <PDB_ID>3M36</PDB_ID>
      <Resolution>2.15</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3M36</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-1H-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor</PubMed_Title>
      <Author>Pruitt, J.R., et al.</Author>
      <Journal>J.Med.Chem.(2003)46:5298-5315</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14640539?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human coagulation factor Xa in complex with M55532</PDB_Title>
      <PDB_ID>1IOE</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IOE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor Xa Specific Inhibitor That Induces the Novel Binding Model In Complex With Human FXa</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Factor XA in complex with the inhibitor (R)-6-(2'-((3- HYDROXYPYRROLIDIN-1-YL)METHYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN- 7(4H)-ONE</PDB_Title>
      <PDB_ID>3FFG</PDB_ID>
      <Resolution>1.54</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FFG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Phenyltriazolinones as potent factor Xa inhibitors.</PubMed_Title>
      <Author>Quan, M.L., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:1373-1377</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20100660?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS</PDB_Title>
      <PDB_ID>2Y81</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Y81</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and Property Based Design of Factor Xa Inhibitors: Pyrrolidin-2-Ones with Aminoindane and Phenylpyrrolidine P4 Motifs.</PubMed_Title>
      <Author>Young, R.J., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:1582-1587</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21349710?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray crystal structure of human fxa in complex with (S)-N-((2-METHYLBENZOFURAN-5-YLAMINO)(2-OXO-1-(2-OXO-2- (PYRROLIDIN-1-YL)ETHYL)AZEPAN-3- YLAMINO)METHYLENE)NICOTINAMIDE</PDB_Title>
      <PDB_ID>3K9X</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3K9X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577</PubMed_Title>
      <Author>Shi, Y., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:6882-6889</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19896847?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Factor xa in complex with the inhibitor n-(3-fluoro-2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-1h- pyrazole-5-carboxamide</PDB_Title>
      <PDB_ID>3KQB</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KQB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Phenyltriazolinones as potent factor Xa inhibitors.</PubMed_Title>
      <Author>Quan, M.L., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:1373-1377</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20100660?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FxA in complex with (S)-2-cyano-1-(2-methylbenzofuran-5-yl)-3-(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-yl)guanidine</PDB_Title>
      <PDB_ID>3HPT</PDB_ID>
      <Resolution>2.19</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HPT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.</PubMed_Title>
      <Author>Shi, Y., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:4034-4041</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19541481?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human coagulation factor Xa in complex with M55125</PDB_Title>
      <PDB_ID>1IQI</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IQI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor Xa Specific Inhibitor that Induces the Novel Binding Model in Complex with Human Fxa</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[[(4,5-dihydro-2-oxazolyl)methylamino]methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa</PDB_Title>
      <PDB_ID>1MQ6</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MQ6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structures of Two Potent Nonamidine Inhibitors Bound to Factor Xa</PubMed_Title>
      <Author>Adler, M., et al.</Author>
      <Journal>Biochemistry(2002)41:15514-15523</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12501180?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Factor XA in complex with the inhibitor N-(2-(((5-chloro-2-pyridinyl) amino)sulfonyl)phenyl)-4-(2-oxo-1(2H)-pyridinyl)benzamide</PDB_Title>
      <PDB_ID>3CEN</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CEN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-Activity Relationships of Anthranilamide-Based Factor Xa  Inhibitors Containing Piperidinone and Pyridinone P4 Moieties</PubMed_Title>
      <Author>Corte, J.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2008)18:2845-2849</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18424044?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human coagulation factor Xa in complex with M54471</PDB_Title>
      <PDB_ID>1IQM</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IQM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor Xa Specific Inhibitor that Induces the Novel Binding Model in Complex with Human Fxa</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125.</PDB_Title>
      <PDB_ID>1LPK</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LPK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and Quantitative Structure-Activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa</PubMed_Title>
      <Author>Matter, H., et al.</Author>
      <Journal>J.Med.Chem.(2002)45:2749-2769</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12061878?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS</PDB_Title>
      <PDB_ID>2Y82</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Y82</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and Property Based Design of Factor Xa Inhibitors: Pyrrolidin-2-Ones with Aminoindane and Phenylpyrrolidine P4 Motifs.</PubMed_Title>
      <Author>Young, R.J., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:1582-1587</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21349710?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Factor xa in complex with the inhibitor 1-(3-(5-oxo-4,5- dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'-(pyrrolidin-1- ylmethyl)biphenyl-4-yl)-3-(trifluoromethyl)-5,6-dihydro- 1h-pyrazolo[3,4-c]pyridin-7(4h)-one</PDB_Title>
      <PDB_ID>3KQD</PDB_ID>
      <Resolution>2.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KQD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Phenyltriazolinones as potent factor Xa inhibitors.</PubMed_Title>
      <Author>Quan, M.L., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:1373-1377</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20100660?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human coagulation factor Xa in complex with M55165</PDB_Title>
      <PDB_ID>1IQF</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IQF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor Xa Specific Inhibitor that Induces the Novel Binding Model in Complex with Human Fxa</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79.</PDB_Title>
      <PDB_ID>1LPG</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LPG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and Quantitative Structure-Activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa.</PubMed_Title>
      <Author>Matter, H., et al.</Author>
      <Journal>J.Med.Chem.(2002)45:2749-2769</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12061878?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR</PDB_Title>
      <PDB_ID>1C5M</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1C5M</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.</PubMed_Title>
      <Author>Katz, B.A., et al.</Author>
      <Journal>Chem.Biol.(2000)7:299-312</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10779411?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Factor XA in complex with the inhibitor 1-[2-(aminomethyl)phenyl]-N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC602)</PDB_Title>
      <PDB_ID>3M37</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3M37</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-1H-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor.</PubMed_Title>
      <Author>Pruitt, J.R., et al.</Author>
      <Journal>J.Med.Chem.(2003)46:5298-5315</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14640539?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Factor Xa in complex with a phenylenediamine derivative</PDB_Title>
      <PDB_ID>3Q3K</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3Q3K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors.</PubMed_Title>
      <Author>Yoshikawa, K., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:2133-2140</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21345673?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human coagulation factor Xa in complex with M55124</PDB_Title>
      <PDB_ID>1IQJ</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IQJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor Xa Specific Inhibitor that Induces the Novel Binding Model in Complex with Human Fxa</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Factor xa in complex with the inhibitor 6-(2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6- dihydro-1h-pyrazolo[3,4-c]pyridin-7(4h)-one</PDB_Title>
      <PDB_ID>3KQC</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KQC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Phenyltriazolinones as potent factor Xa inhibitors.</PubMed_Title>
      <Author>Quan, M.L., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:1373-1377</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20100660?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Factor XA in complex with (R)-2-(1-ADAMANTYLCARBAMOYLAMINO)-3-(3-CARBAMIDOYL-PHENYL)-N-PHENETHYL-PROPIONIC ACID AMIDE</PDB_Title>
      <PDB_ID>3LIW</PDB_ID>
      <Resolution>2.22</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LIW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>(R)-3-Amidinophenylalanine-Derived Inhibitors of Factor Xa with a Novel Active-Site Binding Mode</PubMed_Title>
      <Author>Mueller, M.M., et al.</Author>
      <Journal>Biol.Chem.(2003)383:1185</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12437104?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray crystal structure of human FXA in complex with 6-chloro-N-((3S)-2-oxo-1-(2-oxo-2-((5S)-8-oxo-5,6-dihydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-3(2H,4H,8H)-yl)ethyl)piperidin-3-yl)naphthalene-2-sulfonamide</PDB_Title>
      <PDB_ID>3SW2</PDB_ID>
      <Resolution>2.42</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3SW2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.</PubMed_Title>
      <Author>Shi, Y., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:7516-7521</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22041058?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031) COMPLEXED WITH FACTOR XA</PDB_Title>
      <PDB_ID>1FJS</PDB_ID>
      <Resolution>1.92</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FJS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.</PubMed_Title>
      <Author>Adler, M., et al.</Author>
      <Journal>Biochemistry(2000)39:12534-12542</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11027132?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FXA in complex with methyl (2Z)-3-[(3-chloro-1H-indol-7-yl)amino]-2-cyano-3-{[(3S)-2-oxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)azepan-3-yl]amino}acrylate</PDB_Title>
      <PDB_ID>3ENS</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ENS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, Structure-Activity Relationships, X-ray Crystal Structure, and Energetic Contributions of a Critical P1 Pharmacophore: 3-Chloroindole-7-yl-Based Factor Xa Inhibitors.</PubMed_Title>
      <Author>Shi, Y., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:7541-7551</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18998662?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF HUMAN DES(1-45) FACTOR XA AT 2.2 ANGSTROMS RESOLUTION</PDB_Title>
      <PDB_ID>1HCG</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HCG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of human des(1-45) factor Xa at 2.2 A resolution.</PubMed_Title>
      <Author>Padmanabhan, K., et al.</Author>
      <Journal>J.Mol.Biol.(1993)232:947-966</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8355279?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Factor Xa in complex with a potent 2-amino-ethane sulfonamide inhibitor</PDB_Title>
      <PDB_ID>4A7I</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4A7I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Fragment Deconstruction of Small, Potent Factor Xa Inhibitors: Exploring the Superadditivity Energetics of Fragment Linking in Protein-Ligand Complexes.</PubMed_Title>
      <Author>Nazare, M., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2012)51:905</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22190348?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FACTOR XA INHIBITOR COMPLEX</PDB_Title>
      <PDB_ID>1G2L</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1G2L</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.</PubMed_Title>
      <Author>Nar, H., et al.</Author>
      <Journal>Structure(2001)9:29-38</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11342132?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human coagulation factor Xa in complex with M55590</PDB_Title>
      <PDB_ID>1IQE</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IQE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor Xa Specific Inhibitor that Induces the Novel Binding Model in Complex with Human Fxa</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>COAGULATION FACTOR XA-TRYPSIN CHIMERA INHIBITED WITH D-PHE-PRO-ARG-CHLOROMETHYLKETONE</PDB_Title>
      <PDB_ID>1FXY</PDB_ID>
      <Resolution>2.15</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FXY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>New enzyme lineages by subdomain shuffling.</PubMed_Title>
      <Author>Hopfner, K.P., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1998)95:9813-9818</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9707558?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of 3-chloro-N-[4-chloro-2-[[(4-chlorophenyl)amino]carbonyl]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa</PDB_Title>
      <PDB_ID>1MQ5</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MQ5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structures of Two Potent Nonamidine Inhibitors Bound to Factor Xa</PubMed_Title>
      <Author>Adler, M., et al.</Author>
      <Journal>Biochemistry(2002)41:15514-15523</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12501180?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>COAGULATION FACTOR XA INHIBITOR COMPLEX</PDB_Title>
      <PDB_ID>1FAX</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FAX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition.</PubMed_Title>
      <Author>Brandstetter, H., et al.</Author>
      <Journal>J.Biol.Chem.(1996)271:29988-29992</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8939944?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FACTOR XA INHIBITOR COMPLEX</PDB_Title>
      <PDB_ID>1G2M</PDB_ID>
      <Resolution>3.02</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1G2M</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.</PubMed_Title>
      <Author>Nar, H., et al.</Author>
      <Journal>Structure(2001)9:29-38</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11342132?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Discovery of Tetrahydropyrimidin-2(1H)-one derivative TAK-442: A potent, selective and orally active factor Xa inhibitor</PDB_Title>
      <PDB_ID>3KL6</PDB_ID>
      <Resolution>1.45</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KL6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor.</PubMed_Title>
      <Author>Fujimoto, T., et al.</Author>
      <Journal>J.Med.Chem.(2010)53:3517-3531</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20355714?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human coagulation factor Xa in complex with M55113</PDB_Title>
      <PDB_ID>1IQK</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IQK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor Xa Specific Inhibitor that Induces the Novel Binding Model in Complex with Human Fxa</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208815</PDB_Title>
      <PDB_ID>1F0R</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1F0R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of human factor Xa complexed with potent inhibitors.</PubMed_Title>
      <Author>Maignan, S., et al.</Author>
      <Journal>J.Med.Chem.(2000)43:3226-3232</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10966741?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS</PDB_Title>
      <PDB_ID>2Y80</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Y80</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and Property Based Design of Factor Xa Inhibitors: Pyrrolidin-2-Ones with Aminoindane and Phenylpyrrolidine P4 Motifs.</PubMed_Title>
      <Author>Young, R.J., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)21:1582-1587</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21349710?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human coagulation factor Xa in complex with M55143</PDB_Title>
      <PDB_ID>1IQH</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IQH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor Xa Specific Inhibitor that Induces the Novel Binding Model in Complex with Human Fxa</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45.</PDB_Title>
      <PDB_ID>1LQD</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LQD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and Quantitative Structure-Activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa</PubMed_Title>
      <Author>Matter, H., et al.</Author>
      <Journal>J.Med.Chem.(2002)45:2749-2769</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12061878?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human coagulation factor Xa in complex with M55192</PDB_Title>
      <PDB_ID>1IQN</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IQN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor Xa Specific Inhibitor that Induces the Novel Binding Model in Complex with Human Fxa</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human coagulation factor Xa in complex with M55159</PDB_Title>
      <PDB_ID>1IQG</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IQG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor Xa Specific Inhibitor that Induces the Novel Binding Model in Complex with Human Fxa</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human Coagulation Factor XA Complexed with RPR208707</PDB_Title>
      <PDB_ID>1F0S</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1F0S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of human factor Xa complexed with potent inhibitors.</PubMed_Title>
      <Author>Maignan, S., et al.</Author>
      <Journal>J.Med.Chem.(2000)43:3226-3232</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10966741?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Factor xa in complex with the inhibitor 3-methyl-1-(3-(5- oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'- (pyrrolidin-1-ylmethyl)biphenyl-4-yl)-5,6-dihydro-1h- pyrazolo[3,4-c]pyridin-7(4h)-one</PDB_Title>
      <PDB_ID>3KQE</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KQE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Phenyltriazolinones as potent factor Xa inhibitors.</PubMed_Title>
      <Author>Quan, M.L., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:1373-1377</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20100660?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(4-methoxyphenyl)-6-(4-(1-(pyrrolidin-1-ylmethyl)cyclopropyl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1H-pyrazolo[3,4-c]pyridin-7(4H)-one</PDB_Title>
      <PDB_ID>3CS7</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CS7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa.</PubMed_Title>
      <Author>Qiao, J.X., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2008)18:4118-4123</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18550370?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human Coagulation Factor XA Complexed with FXV673</PDB_Title>
      <PDB_ID>1KSN</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KSN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity.</PubMed_Title>
      <Author>Guertin, K.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2002)12:1671-1674</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12039587?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41.</PDB_Title>
      <PDB_ID>1LPZ</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LPZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and Quantitative Structure-Activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa</PubMed_Title>
      <Author>Matter, H., et al.</Author>
      <Journal>J.Biol.Chem.(2002)45:2749-2769</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12061878?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR128515</PDB_Title>
      <PDB_ID>1EZQ</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1EZQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of human factor Xa complexed with potent inhibitors.</PubMed_Title>
      <Author>Maignan, S., et al.</Author>
      <Journal>J.Med.Chem.(2000)43:3226-3232</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10966741?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Factor XA in complex with a cis-1,2-diaminocyclohexane derivative</PDB_Title>
      <PDB_ID>3IIT</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IIT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: exploration of 6-6 fused rings as alternative S1 moieties.</PubMed_Title>
      <Author>Yoshikawa, K., et al.</Author>
      <Journal>Bioorg.Med.Chem.(2009)17:8221-8233</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19900814?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04610</Pathway_ID>
      <Pathway_Title>Complement and coagulation cascades</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.ia.b.c.ei.html</SCOP_URL>
    <CATH_Class>Class 2: Mainly Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1c5m</CATH_URL>
  </Fold>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>3.4.21.6</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC3/4/21/6.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD04490007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04490008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04490009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04490010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04490011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04490016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04490017</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>